Cancer Therapeutics takes a stake in NanoTherapies

Utah-based Cancer Therapeutics has taken a 25 percent stake in NanoTherapies, a company that's developing therapies for cancer treatment based on calcium phosphate nanoparticles for therapeutic and diagnostic applications. This is Cancer Therapeutics first acquisition; the company said that it's interested in doing additional deals. Release

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.